Contents

Up first

  • Wyoming Immunization Conference
  • Printable posters for your vaccine clinic
  • Provider survey


Public Vaccine Programs

  • Backup generators
  • Ask the Immunization Unit: temperature monitoring over the holidays


WyIR

  • Help Desk 


Resources

  • Start at Age 9 printable toolkit
  • V-safe After Vaccination Health Checker for COVID-19 and monkeypox vaccination
  • No mixing, no diluting: FDA licenses new Rotarix liquid formulation
  • Updated VFC/WyVIP formulary: Vaxneuvance and Priorix
Subscribe to the Jab & Gab

We'd like to hear

from you!

Are you hosting a community event, a health fair or community baby shower? Let us know! We have giveaways for providers, expectant mothers, parents, and adults. Do you have a coworker or clinic that you'd like us to spotlight?

Reach out the the editor at kelly.douglas@wyo.gov.

 

Up first

Wyoming Immunization Conference

Make plans to join the Immunization Unit in Casper May 9, 10, and 11!

Click the image below for more information.

Gingerbread man is ill with flu. Tis the Season. Get the flu shot.

Printable posters for your vaccine clinic


The Wyoming Department of Health vaccination marketing campaign has begun. Watch for ads in newsprint, like and share on social media, and listen for ads on the radio promoting flu vaccination in Wyoming.

Provider toolkit survey


Do you need help promoting vaccinations in your office? 


The Immunization Unit would like to support you! Please fill out this seven-question survey and let us know how we can help you encourage your patients to get vaccinated.


Click Here for the Quick Survey
 

Public Vaccine Programs

Backup generators

Summer Kelly, Public Vaccine Program Coordinator


Proper vaccine storage and handling practices play a very important role in protecting individuals and communities from vaccine-preventable diseases. Power outages are the most common reason that refrigerator and freezer temperatures go out of range. Having an on-site generator prevents the need to transport vaccines to an alternative storage facility during a power outage.


Facilities with generators should:

  • have a contact for a local generator repair company
  • keep sufficient fuel on hand to continuously run the generator for at least 72 hours
  • perform testing quarterly and
  • service the unit annually


For questions about vaccine storage and handling practices, contact Summer Kelly at summer.kelly1@wyo.gov

Ask the Immunization Unit: temperature monitoring over the holidays

Summer Kelly, Public Vaccine Program Coordinator


Question:

Is it necessary for someone to come in to the office and check temperatures when we are closed for the holidays or closed for a long weekend? 


Answer: 

No one needs to come in to monitor temperatures on days the office is closed. Please write or type in “Closed” on the monthly temperature logs for these days. When the office reopens, download and review the temperature data for warming or cooling trends or missed alarms.


Please Note: Temperatures are required to be documented Monday through Friday during normal clinic hours and whenever the clinic is open. If a date on the temperature log is left blank during an office closure, the Immunization Unit will request data logger files for those days. This can delay your monthly vaccine order. 

 

WyIR updates and help desk

WyIR Help Desk

The Wyoming Immunization Registry (WyIR) Help Desk is a Tier One, or user level, service accessible to all WyIR users. 


The Help Desk is the first point of contact for WyIR concerns including; user access, password resets, inventory concerns, reconciliation, reports, patient merges and deduplication, forecast, and more. 


The Help Desk team is committed to responding to most issues within 48 business hours. Issues that cannot be resolved by the Help Desk are escalated to the Immunization Unit via a central email, which is monitored by Immunization Unit staff.


WyIR users are encouraged to contact the Help Desk first instead of reaching out to the Immunization Unit directly, or to individual Immunization Unit staff, who may be out of the office or unable to respond in a timely manner. 


The Help Desk can be reached at:

Phone: 1-833-221-1451

Email: wyir.helpdesk@wyo.gov

OR

utilize the chat feature in the bottom left corner of the WyIR home page.

 

Resources

Start at Age 9 printable toolkit

The National HPV Vaccination Roundtable 11/17/2022 


The COVID-19 pandemic led to substantial declines in HPV vaccinations among adolescents. Current projections estimate that it could take up to 10 years to rebound unless we act proactively. Therefore, we need your help.

 

To assist with getting back on track, the American Cancer Society’s National HPV Vaccination Roundtable has developed the Start at Age 9 toolkit that can be used in your practice and clinics.

 

The toolkit includes:

  • Clinic posters: these are patient-focused and can be displayed throughout your practice.
  • Vaccination schedules: these are patient-focused and can be used when engaging in conversations with patients/parents about what vaccines they have had and which ones they are still missing.
  • Cue card for clinic staff: this card is for staff education and can be displayed in workspaces or at the front desk. Many practices have found them helpful as quick reference guides when talking with parents about vaccinating their children. *Special acknowledgments to the WA HPV Free Taskforce for creating this resource.
  • HPV reminder card and vaccination schedules: these are patient-focused and can be given to a parent as reminders about what vaccine their child received and when the next appointment is scheduled.
  • Check out our new HPVRT YouTube video: “9 Benefits of Age 9”


Download the full Start at Age 9 toolkit below:

https://hpvroundtable.org/wp-content/uploads/2022/11/FINAL_NW-Summit-Clinic-Toolkit-Print-On-Demand-Kits.pdf

V-safe After Vaccination Health Checker for COVID-19 and monkeypox vaccination

Centers for Disease Control and Prevention Communication Email 11/17/2022


CDC’s v-safe after vaccination health checker is a smartphone-based system that uses text messaging and web surveys to provide personalized and confidential health checks. Participants can tell CDC how they, or their child or dependent, feel after they receive any dose of a COVID-19 vaccine (including an updated bivalent booster) or a monkeypox vaccine. Participation in v-safe helps CDC monitor the safety of vaccines.


V-safe is one of several systems CDC uses to monitor vaccine safety. It allows CDC to gather and analyze important information and monitor potential side effects in real time so scientists can quickly determine if there is a safety concern with a particular vaccine. V-safe first launched in 2020 during the COVID-19 pandemic as an innovative vaccine safety monitoring system to gather post-COVID-19 vaccination information from enrolled participants. The v-safe system now offers personalized health checks for those receiving monkeypox vaccine. Participants will need to enroll for v-safe for monkeypox even if they previously enrolled and participated in v-safe for COVID-19, and they can participate in v-safe after their second dose of monkeypox vaccine, even if they did not participate after their first dose.


Learn more about v-safe:

No mixing, no diluting: FDA licenses new Rotarix liquid formulation

IZ Express 11/16/2022


On Nov.4, 2022, the Food and Drug Administration licensed a new formulation of Rotavirus Vaccine, Live, Oral (Rotarix, GSK). The new formulation is free of porcine circovirus (PCV) and comes as a liquid that does not require mixing or dilution. The single dose oral applicator increases provider convenience.

 

Both the lyophilized (requires reconstitution) and liquid rotavirus vaccine presentations will remain in use until the lyophilized formulation is used up or expires.

 

Related Links

Updated VFC/WyVIP formulary: Vaxneuvance and Priorix

Immunization Unit Staff


Vaxneuvance Pneumococcal 15-valent conjugate Merck vaccine and Priorix MMR GSK vaccine will be available to order for Vaccines for Children (VFC) enrolled providers beginning December 1, 2022.


Vaxneuvance (PCV15) can be used interchangeably with Pfizer’s Prevnar13 vaccine (PCV13). Priorix can be used interchangeably with Merck’s M-M-RII vaccine.


If your clinic chooses to switch to one of the newly available vaccine products, we ask that you use your remaining Prevnar13 and/or M-M-RII inventory before switching to a different brand, to minimize vaccine wastage. The Prevnar13 and M-M-RII vaccine presentations will remain on the VFC formulary for ordering. 

 

The following clinical guidance is provided for the VFC use of Vaxneuvance and Priorix vaccines.


Vaxneuvance (PCV15)


Indications and recommendations for use 

PCV vaccine is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae. Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F are included in PCV13; PCV15 contains serotypes 22F and 33F in addition to the PCV13 serotypes. On June 22, 2022, the Advisory Committee on Immunization Practices (ACIP) recommended use of PCV15 as an option for pneumococcal conjugate vaccination of persons aged <19 years, according to currently recommended PCV13 dosing and schedules. Risk-based recommendations on the use of PPSV23 have not changed. 


PCV13 and PCV15:

  • can be used interchangeably. 
  • are recommended for all children aged 2-59 months and some others based on risk factors. 
  • can be administered at the same time as other routine vaccines, including COVID-19, using separate syringes and different injection sites.

ACIP recommends the use of either PCV13 or PCV15 for all children aged 2-59 months. In addition, risk-based PCV use (either PCV13 or PCV15) is recommended for children aged 60-71 months with risk conditions, and persons aged 6-18 years with an immunocompromising condition, cerebrospinal fluid leak, or cochlear implant. For all recommendations, PCV13 and PCV15 can be used interchangeably. Interruption of the vaccination schedule does not require restarting the entire series or adding extra doses. 


Vaccine administration

PCV13 and PCV15 are both available in a single-dose prefilled syringe as a 0.5 mL dose administered intramuscularly. Either PCV13 or PCV15 can be administered at the same time as other routine childhood vaccinations, including COVID-19 vaccines, in separate syringes and using different injection sites. The most common side effects of PCV15 are similar to those seen with PCV13: for children less than 2 years of age - irritability, excess sleepiness, injection site pain, fever, decreased appetite, injection site induration, redness, and/or swelling. Side effects typically go away within three days. 


Recommended schedule and intervals

Infants and young children should receive PCV13 or PCV15 as a 4-dose series at 2, 4, 6, and 12-15 months of age (see table 1). 

Older children through age 59 months may be vaccinated with PCV13 or PCV15 if they did not receive the recommended doses (see table 2). 

Children and adolescents 6-18 years of age with certain medical conditions should receive a single dose of PCV13 or PCV15 if they did not already receive PCV13 or PCV15 (see table 3). 

 

Precautions and contraindications

Vaxneuvance is contraindicated for individuals with a severe allergic reaction (e.g., anaphylaxis) to any component of Vaxneuvance or to diphtheria toxoid. The same precautions used for coadministration of PCV13 and meningococcal vaccines should be applied when PCV15 is used (i.e., for high risk individuals requiring both MCV and PCV vaccinations - MCV4 and PCV must be separated by at least 4 weeks, MCV4O can be given at the same time as PCV). Risk for febrile seizures in children who received PCV15 concurrently with an influenza vaccine has not been studied. Young children may be at increased risk for seizures caused by fever after PCV13 if administered at the same time as inactivated influenza vaccine. Apnea following intramuscular vaccination has been observed in some infants born prematurely. A decision about when to administer Vaxneuvance to infants born prematurely should be based on consideration of the individual infant’s medical status and the potential benefits and possible risks of vaccination. 

 

PCV15 Resources: 

 

Priorix

 

Indications and recommendations for use 

Priorix is indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older. The FDA approved Priorix vaccine on June 3, 2022. No advisory committee meeting was held since a similar vaccine from a different manufacturer has been on the market for many years. In addition, given the similarities in dosage and vaccine components, the evidence from the clinical trials and literature review, the ACIP Work Group considers Priorix and M-M-R-II fully interchangeable, including all off-label uses.

 

Priorix and M-M-RII:

Can be used interchangeably. 

Are recommended for all children aged 12 months of age and older. 

Can be administered at the same time as other routine vaccines, including COVID-19, using separate syringes and different injection sites. 


Priorix (GSK) and M-M-RII (Merck) can be used interchangeably according to the currently recommended MMR dosing and schedules. Like M-M-R-II, Priorix is supplied in lyophilized form and requires reconstitution. Priorix is stored at refrigerated temperatures between 2°C and 8°C (between 36°F and 46°F), and should not be stored in the freezer. Reconstituted vaccine should be used immediately, or stored refrigerated and administered within 8 hours. 

 

Vaccine administration

Priorix is supplied as a single-dose vial of lyophilized antigen component to be reconstituted with the accompanying prefilled syringe of sterile water diluent component. A single dose after reconstitution is approximately 0.5 mL, and should be administered subcutaneously. The first dose is administered at 12 through 15 months of age, and the second dose is administered at 4 through 6 years of age. If either MMR vaccine is not administered according to the routine schedule, there should be a minimum of 4 weeks between the first and second dose. The most common side effects seen with Priorix are similar to those seen with M-M-R-II; pain, redness, swelling at the injection site, irritability, loss of appetite, drowsiness, and fever. Swelling of the parotid glands or temporary pain and stiffness in the joints sometimes occur after MMR vaccination. 

 

Recommended schedule and intervals

Children need 2 doses of MMR vaccine; the first dose at age 12 through 15 months, and the second dose at age 4 through 6 years. 

Infants who will be traveling outside of the United States when they are between 6 and 11 months of age should get a dose of MMR vaccine before travel.  

Older children, adolescents, and adults need 1 or 2 doses of MMR vaccine if they are not already immune to measles, mumps, and rubella. 

If MMR vaccine is not administered according to the routine schedule, there should be a minimum of 4 weeks between the first and second dose.

 

Precautions and contraindications

Contraindications to Priorix include a history of a severe allergic reaction (e.g., anaphylaxis) to any component of Priorix, or after a previous dose of any measles, mumps, and rubella virus-containing vaccine, severe immunodeficiency, and pregnancy. More serious, and rare reactions include seizures or temporary low platelet count. The tip caps of the prefilled syringes of Priorix vaccine contain natural rubber latex, which may cause allergic reactions. Administration of immune globulins and other blood products concurrently with Priorix may interfere with the expected immune response to the vaccine. Priorix may result in a temporary suppression of tuberculin reactivity. 

 

Priorix resources: 

 

Contributors

  • The Wyoming Department of Health Immunization Unit staff
  • American Cancer Society
  • IZ Express
  • The Centers for Disease Control and Prevention


Questions or comments? Email the editor at kelly.douglas@wyo.gov.

Subscribe to the Jab & Gab newsletter
 
 
Facebook  Instagram  YouTube